The clinical utility of DNA-based screening for fetal aneuploidy by primary obstetrical care providers in the general pregnancy population

Genetics in Medicine

Volumn 19, Issue 7, 2017, Pages 778-786

  Palomaki, Glenn E ^a,b   Kloza, Edward M ^a   O'Brien, Barbara M ^a,c   Eklund, Elizabeth E ^a   Lambert Messerlian, Geralyn M ^a,b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

cell free DNA; clinical utility; Down syndrome; patient education; prenatal screening

Indexed keywords

ADULT; ANEUPLOIDY; ARTICLE; CELL FREE SYSTEM; CLINICAL PRACTICE; CLINICAL TRIAL; DNA SCREENING; FEMALE; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NURSE MIDWIFE; NURSE PRACTITIONER; OBSTETRICIAN; PATIENT EDUCATION; PATIENT SATISFACTION; PREGNANCY OUTCOME; TRISOMY 13; TRISOMY 18; TRISOMY 21; ADOLESCENT; BLOOD; DOWN SYNDROME; EDWARDS SYNDROME; FETUS; GENETIC SCREENING; GENETICS; HEALTH PERSONNEL ATTITUDE; MASS SCREENING; MIDDLE AGED; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; PROCEDURES; STANDARDS; TRISOMY; UTILIZATION;

CELL FREE NUCLEIC ACID; DNA;

ADOLESCENT; ADULT; ANEUPLOIDY; ATTITUDE OF HEALTH PERSONNEL; CELL-FREE NUCLEIC ACIDS; CELL-FREE SYSTEM; DNA; DOWN SYNDROME; FEMALE; FETUS; GENETIC TESTING; HUMANS; KNOWLEDGE; MASS SCREENING; MIDDLE AGED; PREGNANCY; PRENATAL CARE; PRENATAL DIAGNOSIS; TRISOMY; TRISOMY 13 SYNDROME; TRISOMY 18 SYNDROME;

EID: 85020068354     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.194     Document Type: Article

References (42)

1. US Department of Health and Human Services. Secretarys Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: recommendations of the SACGT. July 2000. http://osp.od.nih.gov/sites/default/files/oversight-report.pdf. Accessed 29 August 2016.
2. Haddow JE, Palomaki GE. ACCE: A model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W (eds). Human Genome Epidemiology: A Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. Oxford University Press: New York, 2004:217-233.
3. Haddow JE, Palomaki GE. An introduction to assessing genomic screening and diagnostic tests. Nutr Today 2011;46:162-168.
4. Teutsch SM, Bradley LA, Palomaki GE, et al.; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
5. Malone FD, Canick JA, Ball RH, et al.; First-And Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-Trimester or second-Trimester screening, or both, for Downs syndrome. N Engl J Med 2005;353:2001-2011.
6. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-487.
7. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci USA 2008;105:16266-16271.
8. Chiu RW, Chan KC, Gao Y, et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 2008;105:20458-20463.
9. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: An international clinical validation study. Genet Med 2011;13:913-920.
10. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH. Analysis of cellfree DNA in maternal blood in screening for fetal aneuploidies: updated metaanalysis. Ultrasound Obstet Gynecol 2015;45:249-266.
11. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15:395-398.
12. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: A position statement of the American College of Medical Genetics and Genomics. Genet Med 2016;18:1056-1065.
13. ACOG. Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545: American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:1532-1534.
14. Benn P, Borrell A, Cuckle H, et al. Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): A rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn 2012;32:1-2.
15. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: The position of the National Society of Genetic Counselors. J Genet Couns 2013;22:291-295.
16. Langlois S, Brock JA, Wilson RD, et al.; Genetics Committee. Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can 2013;35: 177-183.
17. Dondorp W, de Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 2015;23:1592.
18. Bulletin #36: Prenatal aneuploidy screening using cell-free DNA. Am. J. Obstet. Gynecol. 2015;212:711-716.
19. Hurd WW, Barhan SM, Rogers RE. Obstetrician-gynecologist as primary care provider. Am J Manag Care 2001;7 Spec No:SP19-SP24.
20. Nicolaides KH, Syngelaki A, Gil M, Atanasova V, Markova D. Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33:575-579.
21. Pergament E, Cuckle H, Zimmermann B, et al. Single-nucleotide polymorphismbased noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 2014;124(2 Pt 1):210-218.
22. Doak CC, Doak LG, Root JH. Teaching Patients with Low Literacy Skills, 2nd edn. JB Lippincott: Philadelphia, PA, 1996.
23. Kloza EM, Haddow PK, Halliday JV, OBrien BM, Lambert-Messerlian GM, Palomaki GE. Evaluation of patient education materials: The example of circulating cell free DNA testing for aneuploidy. J Genet Couns 2015;24: 259-266.
24. Bianchi DW, Platt LD, Goldberg JD, Abuhamad AZ, Sehnert AJ, Rava RP; MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901.
25. Mazloom AR, Džakula Z, Oeth P, et al. Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn 2013;33:591-597.
26. Samango-Sprouse C, Banjevic M, Ryan A, et al. SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 2013;33:643-649.
27. Committee Opinion No. 640: Cell-Free DNA Screening For Fetal Aneuploidy. Obstet. Gynecol 2015;126:e31-37.
28. Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn 2010;30:57-64.
29. Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 2013;33:667-674.
30. American College of Obstetrics and Gynecology. Prenatal dection of neural tube defects. ACOG Technical Bulletin 67. October. Washington, DC. 1982.
31. Bianchi DW, Parker RL, Wentworth J, et al.; CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014;370: 799-808.
32. Norton ME, Jacobsson B, Swamy GK, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015;372:1589-1597.
33. Practice bulletin No. 163: screening for fetal aneuploidy. Obstet Gynecol 2016;127:e123-137.
34. Zhang H, Gao Y, Jiang F, et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146, 958 pregnancies. Ultrasound Obstet Gynecol 2015;45:530-538.
35. Bryant AS, Norton ME, Nakagawa S, et al. Variation in Womens Understanding of Prenatal Testing. Obstet Gynecol 2015;125:1306-1312.
36. Farrell R, Hawkins A, Barragan D, Hudgins L, Taylor J. Knowledge, understanding, and uptake of noninvasive prenatal testing among Latina women. Prenat Diagn 2015;35:748-753.
37. Lewis C, Hill M, Skirton H, Chitty LS. Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy. Eur J Hum Genet 2016;24:809-816.
38. Gokhale LS, Cietak KA. Serum screening for anomalies in pregnancy: reasons for acceptance or refusal of the test. J Obstet Gynaecol 2002;22:392-393.
39. Kuppermann M, Pena S, Bishop JT, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: A randomized clinical trial. JAMA 2014;312:1210-1217.
40. Piechan JL, Hines KA, Koller DL, et al. NIPT and informed consent: An assessment of patient understanding of a negative NIPT Result. J Genet Couns 2016;25:1127-1137.
41. Crombag NM, van Schendel RV, Schielen PC, Bensing JM, Henneman L. Present to future: what the reasons for declining first-Trimester combined testing tell us about accepting or declining cell-free DNA testing. Prenat Diagn 2016;36: 587-590.
42. Palomaki GE, Ashwood ER, Best RG, Lambert-Messerlian G, Knight GJ. Is maternal plasma DNA testing impacting serum-based screening for aneuploidy in the United States? Genet Med 2015;17:897-900.